(S)-N-(3,5-bis(trifluoromethyl)benzyl)-7,9-dimethyl-N-(2-methyl-2H-tetrazol-5-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-amine | 1259393-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (S)-N-(3,5-bis(trifluoromethyl)benzyl)-7,9-dimethyl-N-(2-methyl-2H-tetrazol-5-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-amine
• 英文别名: (5S)-N-(3,5-bis(trifluoromethyl)benzyl)-7,9-dimethyl-N-(2-methyl-2H-tetrazol-5-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-amine；(5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,9-dimethyl-N-(2-methyltetrazol-5-yl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-amine
• CAS: 1259393-19-5
• 化学式: C₂₃H₂₄F₆N₆
• 分子量: 498.474
• InChiKey: VVWJIRQQIVAXKX-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58.9
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (S)-N-(3,5-bis(trifluoromethyl)benzyl)-7,9-dimethyl-N-(2-methyl-2H-tetrazol-5-yl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-amine 、 (1R,4R)-Methyl 4-formylcyclohexanecarboxylate 在 platinum on carbon 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 25.0~35.0 ℃ 、344.75 kPa 条件下， 反应 18.0h， 生成 methyl 4-(((S)-5-((3,5-bis(trifluoromethyl)-benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methyl)-cyclohexane-1-carboxylate
  参考文献：
  名称：

  Development of a Hydrogenative Reductive Amination for the Synthesis of Evacetrapib: Unexpected Benefits of Water

  摘要：

  For the synthesis of cholesteryl ester transfer protein (CETP) inhibitor evacetrapib, a hydrogenative reductive amination was chosen to join the substituted cyclohexyl subunit to the benzazepine core. The addition of water, which suppressed undesired epimerization without affecting the rate of product formation, was key to the reaction's success. The process was scaled to produce more than 1100 kg of material.

  DOI：

  10.1021/op500025v
• 作为产物：
  描述：

  (5S)-benzyl 5-((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carboxylate 在 palladium 10% on activated carbon 甲酸铵 作用下， 以 甲醇 为溶剂， 以99.92%的产率得到
  参考文献：
  名称：

  Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

  摘要：

  本发明涉及一种名为trans-4-[[(5S)-5-[[[3,5-双三氟甲基苯基]甲基](2-甲基-2H-四唑-5-基)氨基]-2,3,4,5-四氢-7,9-二甲基-1H-1-苯并氮杂环-1-基]甲基]-环己烷羧酸的化合物，其为自由酸或其药学上可接受的盐；以及在晶体形式下的水合物和其他溶剂化合物；药物制剂；以及使用方法。

  公开号：

  US20100331309A1

文献信息

• Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
  申请人：Chen Xinchao

  公开号：US20120058990A1

  公开（公告）日：2012-03-08

  Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.

  本发明涉及一种名为trans-4-[[(5S)-5-[[[3,5-双三氟甲基苯基]甲基](2-甲基-2H-四唑-5-基)氨基]-2,3,4,5-四氢-7,9-二甲基-1H-1-苯并氮杂环-1-基]甲基]-环己烷羧酸的化合物，其可以是自由酸或其药学上可接受的盐，水合物以及晶体形式的水合物；药物制剂；以及使用方法。
• TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETHYL)PHENYL]METHYL](2-METHYL-2H-TETRAZOL-5-YL)AMINO]-2,3,4,5-TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-YL]METHYL]-CYCLOHEXANECARBOXYLIC ACID
  申请人：Eli Lilly and Company

  公开号：EP2448933A1

  公开（公告）日：2012-05-09
• US8299060B2
  申请人：——

  公开号：US8299060B2

  公开（公告）日：2012-10-30
• US8329688B2
  申请人：——

  公开号：US8329688B2

  公开（公告）日：2012-12-11
• [EN] TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETHYL)PHENYL]METHYL] (2-METHYL-2H-TETRAZOL-5-YL)AMINO]-2,3,4,5-TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-YL]METHYL]-CYCLOHEXANECARBOXYLIC ACID<br/>[FR] ACIDE TRANS-4-[[(5S)-5-[[[3,5-BIS (TRIFLUOROMÉTHYLE) PHÉNYLE] MÉTHYLE] (2-MÉTHYL-2H-TÉTRAZOL-5-YLE) AMINO]-2,3,4,5-TÉTRAHYDRO-7,9-DIMÉTHYL-1H-1-BENZAZÉPIN-1-YLE] MÉTHYLE]-CYCLOHEXANE CARBOXYLIQUE
  申请人：LILLY CO ELI

  公开号：WO2011002696A1

  公开（公告）日：2011-01-06

  Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol- 5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]- cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.